Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 9.35 Billion | USD 16.91 Billion | 6.8% | 2023 |
The global Osteoarthritis Drug Market size was worth around USD 9.35 billion in 2023 and is predicted to grow to around USD 16.91 billion by 2032 with a compound annual growth rate (CAGR) of roughly 6.8% between 2024 and 2032.
The study provides historical data from 2018 to 2022 along with a forecast from 2024 to 2032 based on revenue (USD billion). The report covers a forecast and an analysis of the Osteoarthritis Drug Market on a global and regional level.
Osteoarthritis is a joint degenerative disorder that affects various joint, which mostly affects the elderly population. In osteoarthritis, the smooth gliding surface between joints that provides easy movement is affected with age. This leads to swelling, pain, tenderness, and stiffness in joints and affects the normal movement and quality of life of an individual. There is no permanent cure for this condition. However, medicines help in suppressing the symptoms to a certain extent, thereby offering relief to patients. The medications used for the osteoarthritis treatment mostly include pain relievers, such as Paracetamol, ibuprofen, naproxen, etc. Osteoarthritis affects the knee, shoulder, lower back, etc.
The primary factor likely to drive the global osteoarthritis drug market over the estimated timeframe is the constantly rising aging population. As per the National Institutes of Health Report, in 2017, nearly 617 million people were 65 years and above. This number is projected to reach around 1.6 billion by the year 2050. The growing prevalence of osteoarthritis among people is another factor expected to promote the expansion of osteoarthritis drug market globally in the future. As per the Centers for Disease Control and Prevention report 2017, there were around 30 million adults in the U.S. suffered from osteoarthritis. FDA approvals for various drugs are expected to create new growth opportunities in this market. Moreover, increasing research and development activities and innovation of new drugs are also expected to support the growth of the global osteoarthritis drug market over the estimated timeframe. However, the low adoption rate and side effects of these drugs might hamper the growth of the osteoarthritis drug market in the future.
The study provides a decisive view of the osteoarthritis drug market by segmenting the market based on drug class, route of administration, distribution channel, and region. All the segments have been analyzed based on present and future trends and the market are estimated from 2024 to 2032.
By drug class, the osteoarthritis drug market is segmented into corticosteroids, NSAIDs, viscosupplementation agents, and others. Viscosupplementation agents are expected to expand significantly over the forecast time period.
By route of administration, this market is segmented into oral, parenteral, and topical. The parenteral segment is expected to dominate this global market over the forecast timespan.
The distribution channel segment includes hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies are expected to hold a major market share in the upcoming years.
Report Attributes | Report Details |
---|---|
Report Name | Osteoarthritis Drug Market |
Market Size in 2023 | USD 9.35 Billion |
Market Forecast in 2032 | USD 16.91 Billion |
Growth Rate | CAGR of 6.8% |
Number of Pages | 110 |
Key Companies Covered | Pfizer Inc., Horizon Pharma plc, Ferring B.V., Bioventus, Inc., Sanofi, Flexion Therapeutics, Inc., Alkem Laboratories, Anika Therapeutics, Inc., Chugai Pharmaceutical Co., Limited, and Zimmer Biomet Holdings, Inc., among others |
Segments Covered | By drug class, By route of administration, By distribution channel and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa comprise the regional segmentation of the global osteoarthritis drug market. North America is expected to dominate the global osteoarthritis drug market in the future, due to the presence of developed economies, such as the U.S. and Canada. Europe is anticipated to be the second largest region in the osteoarthritis drug market in the upcoming years, owing to the presence of advanced technology. The Asia Pacific osteoarthritis drug market is the third largest and likely to emerge as the fastest growing over the forecast period, owing to the presence of developing economies, such as India and China. The Latin American and the Middle Eastern and African markets are expected to register a sluggish rate of growth over the forecast timeline.
Some major players of the global osteoarthritis drug market include:
Global Osteoarthritis Drug Market: Drug Class Analysis
Global Osteoarthritis Drug Market: Route of Administration Analysis
Global Osteoarthritis Drug Market: Distribution Channel Analysis
Global Osteoarthritis Drug Market: Regional Analysis
FrequentlyAsked Questions
Osteoarthritis is a joint degenerative disorder that affects various joint, which mostly affects the elderly population. In osteoarthritis, the smooth gliding surface between joints that provides easy movement is affected with age.
According to study, the Osteoarthritis Drug Market size was worth around USD 9.35 billion in 2023 and is predicted to grow to around USD 16.91 billion by 2032.
The CAGR value of Osteoarthritis Drug Market is expected to be around 6.8% during 2024-2032.
North America has been leading the Osteoarthritis Drug Market and is anticipated to continue on the dominant position in the years to come.
The Osteoarthritis Drug Market is led by players like Pfizer Inc., Horizon Pharma plc, Ferring B.V., Bioventus Inc., Sanofi, Flexion Therapeutics Inc., Alkem Laboratories, Anika Therapeutics Inc., Chugai Pharmaceutical Co., Limited, and Zimmer Biomet Holdings Inc., among others.
RelatedNews
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed